Advertisement
Eli Lilly
Subscribe to Eli Lilly

The Lead

Eli Lilly Bumps Dividend for First Time Since 2009

December 16, 2014 10:54 am | News | Comments

Lilly has been dealing with a drop in both earnings and revenue due to the loss of patents protecting key drugs from cheaper generic competition. Company executives have said they remained committed to the dividend, despite the financial blows the company was absorbing, but some analysts have questioned whether that commitment might waver.

Lilly's Cyramza Gets New Marketing Approval

December 15, 2014 8:12 am | News | Comments

The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases...

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent...

Charges Dropped Against Two Former Lilly Scientists

December 8, 2014 8:34 am | News | Comments

Two former Eli Lilly and Co. employees who were accused of sending trade secrets worth more than...

View Sample

FREE Email Newsletter

Lilly and Zosano Form $440M Osteoporosis Patch Deal

December 2, 2014 3:42 pm | News | Comments

Eli Lilly will invest $15 million in Zosano, which filed for an initial public offering earlier this year. Zosano, of Fremont, California, could get $300 million if its drug advances through regulatory review and another $125 million if it reaches sales targets.

Eli Lilly and AstraZeneca Start Pivotal Clinical Trial for Patients with Early Alzheimer's Disease

December 1, 2014 8:22 am | News | Comments

Eli Lilly and and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

Fifth Person Pleads Guilty in Eli Lilly Drug Warehouse Heist

November 25, 2014 10:09 pm | by The Associated Press | News | Comments

A fifth person has pleaded guilty to participating in a 2010 Connecticut warehouse heist that prosecutors say involved up to $100 million in prescription drugs. Cuban citizen and Miami resident Rafael Lopez pleaded guilty to a federal charge of deliberately hiding his knowledge of a felony.

Advertisement

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance

October 29, 2014 8:19 am | News | Comments

In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company are changing the operational and financial structure of their diabetes alliance in certain countries.

Patent Expirations Hit Eli Lilly Third Quarter Profit

October 23, 2014 1:43 pm | News | Comments

Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant Cymbalta lost patent protection and faced competition from less-expensive generics. Lilly said its revenue from Cymbalta plunged 73%t and revenue from the osteoporosis treatment Evista fell 65%.

Eli Lilly Adds $375M to Zymeworks Partnership

October 22, 2014 5:37 pm | by The Associated Press | News | Comments

The companies announced a team-up in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375M in milestones and other payments.     

FDA Accepts NDA for Empagliflozin/Metformin Fixed-Dose Combination

October 21, 2014 9:01 am | News | Comments

The FDA has accepted the filing of a New Drug Application for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes.  

Lilly to Realign Puerto Rico Manufacturing Operations

October 16, 2014 3:28 pm | News | Comments

Eli Lilly and Company has announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. 

Advertisement

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.

EU OKs Eli Lilly's $5.4B Bid for Novartis division

October 3, 2014 6:47 am | by The Associated Press | News | Comments

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors.

Lilly Ends Lupus Drug Development Program

October 2, 2014 8:48 am | News | Comments

Eli Lilly and Company will discontinue development of tabalumab -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials.     

FDA Approves Eli Lilly's Injectable Diabetes Drug

September 18, 2014 4:46 pm | by The Associated Press | News | Comments

The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease. The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes.

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.  

Advertisement

Lilly Says CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

September 12, 2014 8:56 am | News | Comments

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.   

Lilly Receives European Marketing OK for Insulin

September 10, 2014 10:58 am | News | Comments

European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent infringement litigation with French rival Sanofi.        

Lilly Says Insulin Fares Well in Late-Stage Tests

September 4, 2014 11:51 am | News | Comments

Lilly said peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.       

Court Orders Takeda to Pay $6B Over Actos Diabetes Drug

September 4, 2014 10:51 am | News | Comments

Takeda Pharmaceutical has been ordered by a U.S. district court to pay $6 billion in punitive damages over a lawsuit filed by a man who claimed his bladder cancer was caused by Takeda's diabetes medicine Actos.       

Eli Lilly to Close Terre Haute Animal Enzyme Plant

August 14, 2014 8:02 am | News | Comments

Eli Lilly and Co. says it will close its Elanco animal enzyme plant in Terre Haute by early 2016 as part of a consolidation push. Lilly spokesman Ed Sagebiel tells the Tribune-Star the Indianapolis-based company is consolidating all of its animal enzyme manufacturing to a site in Great Britain.

FDA Approves Lilly, Boehringer Diabetes Drug

August 1, 2014 1:34 pm | by The Associated Press | News | Comments

Federal regulators have approved a new treatment from U.S. drugmaker Eli Lilly and Co. and its German counterpart, Boehringer Ingelheim, for the most common form of diabetes . The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes.

Lilly Second Quarter Profit Falls 39%

July 24, 2014 7:31 am | by The Associated Press | News | Comments

Eli Lilly and Co. (LLY) on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations. The Indianapolis-based company said earnings declined to $733.5 million, or 68 cents per share, from $1.21 billion, or $1.11 per share, in the same quarter a year earlier.

Anthera Pharmaceuticals Acquires Sollpur for Exocrine Pancreatic Insufficiency From Eli Lilly

July 15, 2014 9:04 am | News | Comments

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.   

CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union

June 27, 2014 8:20 am | News | Comments

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.   

Analyst: Sanofi Facing Triple Threat from Eli Lilly for Diabetes Treatment Market Space

June 25, 2014 8:13 am | News | Comments

The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase its share of the diabetes treatment market, and the US-based company has three big weapons in its pharmaceutical arsenal, says an analyst with research and consulting firm GlobalData.

Lilly Declares Q3 2014 Dividend

June 16, 2014 3:02 pm | by Lilly | News | Comments

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2014 of $0.49 per share on outstanding common stock.                                        

Lilly Announces Results Of Phase III Hepatocellular Carcinoma Trial

June 11, 2014 8:16 am | News | Comments

Eli Lilly and Company today announced that the Phase III REACH trial of CYRAMZA (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading